TYRA Biosciences is a clinical-stage biotechnology company developing precision medicines focused on fibroblast growth factor receptor (FGFR) biology for targeted oncology and genetically defined conditions. The company's core asset is dabogratinib, a highly selective FGFR3 inhibitor designed to minimize the toxicities associated with earlier pan-FGFR inhibitors, currently being advanced in multiple Phase 2 trials across urothelial cancers and achondroplasia with the potential to address substantial unmet medical needs in these patient populations. TYRA operates a proprietary SNÅP drug design platform that combines protein crystallography, cell-based assays, and in vivo models to enable rapid iterative development and generate structural insights to predict drug potency, selectivity, and tolerability before clinical testing, and plans to retain development and commercialization rights while selectively pursuing partnerships for indications or regions better suited to larger pharmaceutical resources.